TRIPTORELIN

Information current as at: 1 July 2026

PBAC meeting date: November 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Diphereline®
Form and strength:
  • Intramuscular (I.M.) injection 3.75 mg with solvent, syringe and needles
Submission sponsor:
IPSEN PTY LTD
Condition/indication:
(therapeutic use)
  • Treatment with gonadotrophin releasing hormone (GnRH) agonist
Listing requested:
To request a change to the PBS listing for triptorelin 3.75 mg I.M. injection to support its use across a number of women’s health conditions.
Funding program:
General schedule
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
Change to existing listing (–)
Comment:
Special Out of Session July 2026 PBAC Meeting
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2026 PBAC meeting
Opportunity for consumer comment:
--
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1317
Page last updated
28 July 2026
Return to the Medicine Status Listing
v.9.19